Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

453

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

November 30, 2027

Study Completion Date

May 31, 2028

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

R-CHOP

Arm A patients will receive R-CHOP alone.

DRUG

R-CHOP + acalabrutinib

Arm B patients will receive R-CHOP in combination with acalabrutinib.

Trial Locations (33)

Unknown

Colchester General Hospital, Colchester

East Kent Hospitals NHS Foundation Trust, Canterbury

Monklands Hospital, Airdrie

Victoria Hospital, Blackpool

University Hospital Dorset NHS Foundation Trust (Bournemouth and Poole Hospitals), Bournemouth

Queens Hospital, Burton-on-Trent

Addenbrooke's Hospital, Cambridge

Royal Derby Hospital, Derby

Royal Devon and Exeter Hospital, Exeter

Beatson West of Scotland Cancer Centre, Glasgow

Ipswich Hospital, Ipswich

St James Hospital, Leeds

Leicester Royal Infirmary, Leicester

Chase Farm and Barnet Hospitals, London

Lewisham and Greenwich NHS Trust, London

University College London Hospital, London

Maidstone Hospital, Maidstone

The Christie Hospital, Manchester

Milton Keynes University Hospital, Milton Keynes

Freeman Hospital, Newcastle

Norfolk and Norwich University Hospital, Norwich

Nottingham City Hospital, Nottingham

Royal Oldham Hospital, Oldham

Churchill Hospital, Oxford

Derriford Hospital, Plymouth

Queen Alexandra Hospital, Portsmouth

Queen's Hospital, Romford

Southampton General Hospital, Southampton

Royal Stoke University Hospital, Stoke-on-Trent

Singleton Hospital, Swansea

Torbay Hospital, Torquay

Royal Cornwall Hospital, Truro

Worthing and St Richards Hospitals, Worthing

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University Hospital Southampton NHS Foundation Trust

OTHER